The FDA has approved Alnylam’s gene silencing drug ... As the kidney function worsens, oxalate can build up and damage other organs including the heart, bones and eyes. The disease is also ...

Novartis has claimed accelerated approval from the FDA for a second ... are at risk of rapid disease progression, making it the first complement inhibitor for the rare kidney disease.

John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...

American adults with chronic kidney disease ... found that of 506 drugs in company pipelines, only 6 are antibiotics. One of those drugs, telithromycin, was approved by the FDA in April.

The FDA will decide on new drugs for rosacea, AADC deficiency, breast cancer, transthyretin amyloid cardiomyopathy, and biliary tract cancer.

The FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance) and ...

It is also approved to prevent flea infestations and heartworm disease in dogs. The company expects to launch the drug in the first quarter of 2025. "We see this innovation will expand the market ...

It is also approved to prevent flea infestations and heartworm disease in dogs. The company expects to launch the drug in the first quarter of 2025.

The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...

The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.